陈汉川,何浩铭,何晨,严晗,王孙蓥,陈希男,朱鹏立,郭延松,林开阳

• 1:福建医科大学省立临床医学院福建省立医院心内三科
• 2:福建医科大学省立临床医学院福建省立医院老年科
• 3:福建省临床老年病研究所

摘要(Abstract)：

<正>对比剂诱导急性肾损伤(contrast-induced acute kidney injury,CI-AKI)也称为对比剂肾病(contrast-induced nephropathy,CIN),是对比剂使用后常见的并发症。随着放射学和心脏病学的发展,越来越多的患者接受CT检查和经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)。由于对比剂的使用越来越普遍,伴随而来的是CI-AKI这一严重并发症的增加。CI-AKI的发生会延长患者住院时间,增加医疗费用,增加透析、死亡等风险,严重影响患者健康,加重社会经济负担。然而,目前临床上针对CI-AKI尚缺乏有效的治疗手段,预防显得尤为重要。目前公认的有效预防CI-AKI的策略主要是充分水化和减少对比剂用量,然而其在

关键词(KeyWords)： 对比剂诱导急性肾损伤;预防;水化;经皮冠状动脉介入治疗;介入放射学

Abstract:

Keywords:

基金项目(Foundation): 福建省自然科学基金项目（2017J01171）;; 福建医科大学启航基金项目（2016QH113）;; 福建省卫生计生面向农村和城市社区推广适宜技术项目（2017010）

作者(Author): 陈汉川,何浩铭,何晨,严晗,王孙蓥,陈希男,朱鹏立,郭延松,林开阳

参考文献(References)：

• [1] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J, 2019,20(7-8 Suppl 1):1S-61S.
• [2] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 2012, 120(4):179-184.
• [3] van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury-part 1:definition, clinical features, incidence, role of contrast medium and risk factors:recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol,2018, 28(7):2845-2855.
• [4] Lin KY, Zheng WP, Bei WJ, et al. A novel risk score model for prediction of contrast-induced nephropathy after emergent percutaneous coronary intervention. Int J Cardiol, 2017, 230:402-412.
• [5] Narula A, Mehran R, Weisz G, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention:results from the HORIZONS-AMI substudy. Eur Heart J,2014, 35(23):1533-1540.
• [6] Wichmann JL, Katzberg RW, Litwin SE, et al. Contrast-Induced Nephropathy. Circulation, 2015, 132(20):1931-1936.
• [7]邹古明，颜红兵.造影剂肾病的诊断与治疗现状.中国介入心脏病学杂志，2005,15(3):194-196.
• [8] Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy:results of the P.R.I.N.C.E. study. prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol, 1999, 33(2):403-411.
• [9] Majumdar SR, Kjellstrand CM, Tymchak WJ, et al. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography:a randomized controlled trial. Am J Kidney Dis, 2009, 54(4):602-609.
• [10] Dorval JF, Dixon SR, Zelman RB, et al. Feasibility study of the Renal Guard TM balanced hydration system:A novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Int J Cardiol, 2013, 166(2):482.
• [11] Briguori C, Visconti G, Focaccio A, et al. Renal insufficiency after contrast media administration trialⅡ（REMEDIALⅡ）：Renal Guard system in high-risk patients for contrast-induced acute kidney injury. Circulation, 2011, 124(11):1260-1269.
• [12] Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration:the MYTHOS(induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention)trial. JACC Cardiovasc Interv, 2012, 5(1):90-97.
• [13] Usmiani T, Andreis A, Budano C, et al. AKIGUARD(Acute Kidney Injury GUARding Device)trial:in-hospital and one-year outcomes. J Cardiovasc Med(Hagerstown), 2016, 17(7):530-537.
• [14] Briguori C, Visconti G, Donahue M, et al. Renalguard system in high-risk patients for contrast-induced acute kidney injury. Am Heart J, 2016, 173:67-76.
• [15] Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury:the POSEIDON randomised controlled trial. Lancet,2014, 383(9931):1814-1823.
• [16] Qian G, Fu Z, Guo J, et al. Prevention of contrast-induced nephropathy by central venous pressure-guidedfluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv, 2016, 9(1):89-96.
• [17] Chen H, Wu B, Gong D, et al. Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome:a prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic peptide measurement. Crit Care, 2015, 19:135.
• [18] Rhee H, Jang KS, Shin MJ, et al. Use of multifrequency bioimpedance analysis in male patients with acute kidney injury who are undergoing continuous veno-venous hemodiafiltration. PLo S One, 2015, 10(7):e0133199.
• [19] Maioli M, Toso A, Leoncini M, et al. Pre-procedural bioimpedance vectorial analysis offluid status and prediction of contrast-induced acute kidney injury. J Am Coll Cardiol, 2014, 63(14):1387-1394.
• [20] Maioli M, Toso A, Leoncini M, et al. Bioimpedance-guided hydration for the prevention of contrast-induced kidney injury:the HYDRA study. J Am Coll Cardiol, 2018, 71(25):2880-2889.
• [21]陈韵岱，陈纪言，傅国胜，等.碘对比剂血管造影应用相关不良反应中国专家共识.中国介入心脏病学杂志，2014,22(6):341-348.
• [22] Kaye DM, Stub D, Mak V, et al. Reducing iodinated contrast volume by manipulating in jection pressure during coronary angiography. Catheter Cardiovasc Interv, 2014, 83(5):741-745.
• [23] Mehran R, Faggioni M, Chandrasekhar J, et al. Eff ect of a contrast modulation system on contrast media use and the rate of acute kidney injury after coronary angiography. JACC Cardiovasc Interv,2018, 11(16):1601-1610.
• [24] Desch S, Fuernau G, P?ss J, et al. Impact of a novel contrast reduction system on contrast savings in coronary angiography-the DyeVert randomised controlled trial. Int J Cardiol, 2018,257:50-53.